Sonnet BioTherapeutics Holdings, Inc. (SONN): Price and Financial Metrics

Sonnet BioTherapeutics Holdings, Inc. (SONN): $1.16

0.05 (+4.50%)

POWR Rating

Component Grades













Add SONN to Watchlist
Sign Up

Industry: Biotech



in industry


  • SONN scores best on the Sentiment dimension, with a Sentiment rank ahead of 89.32% of US stocks.
  • SONN's strongest trending metric is Stability; it's been moving up over the last 75 days.
  • SONN ranks lowest in Stability; there it ranks in the 3rd percentile.

SONN Stock Summary

  • With a market capitalization of $8,806,913, SONNET BIOTHERAPEUTICS HOLDINGS INC has a greater market value than merely 2.73% of US stocks.
  • The ratio of debt to operating expenses for SONNET BIOTHERAPEUTICS HOLDINGS INC is higher than it is for about only 5.17% of US stocks.
  • In terms of volatility of its share price, SONN is more volatile than 97.51% of stocks we're observing.
  • If you're looking for stocks that are quantitatively similar to SONNET BIOTHERAPEUTICS HOLDINGS INC, a group of peers worth examining would be DBVT, CANF, VCNX, IPSC, and PULM.
  • SONN's SEC filings can be seen here. And to visit SONNET BIOTHERAPEUTICS HOLDINGS INC's official web site, go to

SONN Valuation Summary

  • In comparison to the median Healthcare stock, SONN's price/sales ratio is 1139.02% higher, now standing at 25.4.
  • Over the past 198 months, SONN's price/sales ratio has gone down 170.5.

Below are key valuation metrics over time for SONN.

Stock Date P/S P/B P/E EV/EBIT
SONN 2023-01-20 25.4 -3.5 -0.3 -0.2
SONN 2023-01-19 27.4 -3.8 -0.3 -0.2
SONN 2023-01-18 28.6 -3.9 -0.3 -0.2
SONN 2023-01-17 31.1 -4.3 -0.4 -0.3
SONN 2023-01-13 32.0 -4.4 -0.4 -0.3
SONN 2023-01-12 32.0 -4.4 -0.4 -0.3

SONN Growth Metrics

    The 2 year net cashflow from operations growth rate now stands at -380.36%.
  • The 4 year revenue growth rate now stands at -38.18%.
  • Its 4 year cash and equivalents growth rate is now at 97.71%.
Over the past 33 months, SONN's revenue has gone down $29,793,175.

The table below shows SONN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 0.349943 -27.68728 -29.72184
2022-06-30 0.770816 -27.46372 -29.23857
2022-03-31 0.708745 -25.48387 -27.47709
2021-12-31 0.613425 -25.66291 -25.3077
2021-09-30 0.483626 -22.55224 -24.98396
2021-06-30 0 -22.15688 -66.89109

SONN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • SONN has a Quality Grade of D, ranking ahead of 9.63% of graded US stocks.
  • SONN's asset turnover comes in at 0 -- ranking 440th of 681 Pharmaceutical Products stocks.
  • QGEN, ALNY, and RDUS are the stocks whose asset turnover ratios are most correlated with SONN.

The table below shows SONN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.000 NA 6.121
2021-03-30 0.000 NA 8.723
2020-12-31 0.492 0.045 -7.708
2020-09-30 0.000 NA -2.244
2020-06-30 0.549 0.025 -1.292
2020-03-31 0.683 0.039 -0.581

SONN Price Target

For more insight on analysts targets of SONN, see our SONN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $6.50 Average Broker Recommendation 1.25 (Strong Buy)

SONN Stock Price Chart Interactive Chart >

Price chart for SONN

SONN Price/Volume Stats

Current price $1.16 52-week high $9.37
Prev. close $1.11 52-week low $0.91
Day low $1.10 Volume 115,461
Day high $1.17 Avg. volume 1,155,428
50-day MA $1.12 Dividend yield N/A
200-day MA $2.64 Market Cap 9.92M

Sonnet BioTherapeutics Holdings, Inc. (SONN) Company Bio

Sonnet BioTherapeutics Holdings, Inc. operates as a clinical stage biotechnology company. The Company develops fully human albumin binding technology that helps the development of innovative targeted biologic drugs with enhanced single-or bi-specific mechanisms. Sonnet BioTherapeutics Holdings serves customers in the United States.

SONN Latest News Stream

Event/Time News Detail
Loading, please wait...

SONN Latest Social Stream

Loading social stream, please wait...

View Full SONN Social Stream

Latest SONN News From Around the Web

Below are the latest news stories about SONNET BIOTHERAPEUTICS HOLDINGS INC that investors may wish to consider to help them evaluate SONN as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

It's the final day of trading this week and we're checking in on the biggest pre-market stock movers for Friday morning!

William White on InvestorPlace | January 20, 2023

Sonnet Biotherapeutics announces data from a phase 1 dose-escalation trial of SON-1010

  • Sonnet BioTherapeutics (NASDAQ:SONN) said it had dosed 24 volunteers in a phase 1 study to test SON-1010, to treat tumors, without the background of prior chemotherapy.
  • Pharmacokinetic data showed an extended half-life of SON-1010 of approximately 112 hours, compared to 12 hours for recombinant human interleukin-12.
  • The trial showed that simulation of the controlled...

    Seeking Alpha | January 19, 2023

Sonnet BioTherapeutics Announces Pharmacokinetic and Pharmacodynamic Data in a Phase 1 Dose-Escalation Trial of SON-1010

Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing targeted immunotherapeutic drugs, announced today that pharmacokinetic (PK) profile simulation of SON-1010 dosing has been completed in its randomized, placebo-controlled Phase 1 clinical trial in healthy volunteers.

Yahoo | January 19, 2023

Sonnet BioTherapeutics Shares Up 8% on Roche Collaboration

By Josh Beckerman Shares of Sonnet BioTherapeutics Holdings Inc. were up 8% to $1.40 after it announced a clinical collaboration agreement with Roche Holding…

MarketWatch | January 9, 2023

Sonnet BioTherapeutics Announces a Collaboration with Roche for the Clinical Evaluation of SON-1010 with atezolizumab in Ovarian Cancer

Sonnet''s lead product, SON-1010, to be evaluated in combination with Roche''s atezolizumab (Tecentriq®)Sonnet will sponsor the clinical study in patients with platinum-resistant ovarian cancer, scheduled to commence during the second calendar quarter …

Wallstreet:Online | January 9, 2023

Read More 'SONN' Stories Here

SONN Price Returns

1-mo 11.54%
3-mo 0.00%
6-mo -69.79%
1-year -71.62%
3-year -99.49%
5-year -99.91%
YTD 0.87%
2022 -80.12%
2021 -81.48%
2020 -85.46%
2019 -54.26%
2018 -50.95%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7196 seconds.